Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.
about
HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrationsMajor depletion of plasmacytoid dendritic cells in HIV-2 infection, an attenuated form of HIV diseaseClinical prognostic value of RNA viral load and CD4 cell counts during untreated HIV-1 infection--a quantitative review.Evolution of the human immunodeficiency virus type 2 envelope in the first years of infection is associated with the dynamics of the neutralizing antibody response.HIV shedding in the oral cavity: an assessment of HIV type, immunovirologic, demographic and oral factors.HIV-1 outcompetes HIV-2 in dually infected Senegalese individuals with low CD4⁺ cell countsFrequent CXCR4 tropism of HIV-1 subtype A and CRF02_AG during late-stage disease--indication of an evolving epidemic in West AfricaHIV-2 genetic evolution in patients with advanced disease is faster than that in matched HIV-1 patients.Plasma RNA viral load in human immunodeficiency virus type 2 subtype A and subtype B infectionsHuman immunodeficiency virus superinfection and recombination: current state of knowledge and potential clinical consequences.Cell-associated viral burden provides evidence of ongoing viral replication in aviremic HIV-2-infected patientsUpdate on human immunodeficiency virus (HIV)-2 infection.Genomic sites of human immunodeficiency virus type 2 (HIV-2) integration: similarities to HIV-1 in vitro and possible differences in vivo.Increased frequency of circulating CCR5+ CD4+ T cells in human immunodeficiency virus type 2 infectionPotent intratype neutralizing activity distinguishes human immunodeficiency virus type 2 (HIV-2) from HIV-1Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infectionsDirect evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infectionRole of human immunodeficiency virus (HIV)-specific T-cell immunity in control of dual HIV-1 and HIV-2 infection.Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection.Importance of an Early HIV Antibody Differentiation Immunoassay for Detection of Dual Infection with HIV-1 and HIV-2Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France.Single-Strand Consensus Sequencing Reveals that HIV Type but not Subtype Significantly Impacts Viral Mutation Frequencies and Spectra.Theoretical design of a gene therapy to prevent AIDS but not human immunodeficiency virus type 1 infectionEffect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Frequent intratype neutralization by plasma immunoglobulin a identified in HIV type 2 infection.HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs.Elevated levels of invariant natural killer T-cell and natural killer cell activation correlate with disease progression in HIV-1 and HIV-2 infections.Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.A call for randomized controlled trials of antiretroviral therapy for HIV-2 infection in West Africa.Tenets of protection from progression to AIDS: lessons from the immune responses to HIV-2 infection.HIV-2 Infection: Where Are We Today?CD4+ T cells with an activated and exhausted phenotype distinguish immunodeficiency during aviremic HIV-2 infection.Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4.Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau.Baseline characteristics, response to and outcome of antiretroviral therapy among patients with HIV-1, HIV-2 and dual infection in Burkina Faso.High level of susceptibility to human TRIM5α conferred by HIV-2 capsid sequences.The role of the humoral immune response in the molecular evolution of the envelope C2, V3 and C3 regions in chronically HIV-2 infected patients.Human immunodeficiency virus (HIV)-2-specific T lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau.Clinical progression in early and late stages of disease in a cohort of individuals infected with human immunodeficiency virus-2 in Guinea-Bissau.
P2860
Q27355483-4B5786A8-51B2-4740-9280-58DDDBB175B3Q30912292-FEDB93DE-F139-4EF9-9F8B-3804C90947DFQ33470290-7AB7DCBF-1305-4E53-96F0-DCD41D2B75BBQ33591409-C81FEE8E-F807-4DEE-AEB4-CA69434571BFQ33638612-2A679A32-9652-4339-BFA0-E12DDDD57ADDQ33705170-44F0B8D6-52EE-47DC-98B1-4BDACF25268CQ33793066-3A797A78-35F7-4099-9AF3-A24F3411BD89Q33966596-C12D7BAB-372F-45AA-AB50-B9769BF8737CQ34199460-7A3CC175-D539-471B-B833-6B7680F2B5C9Q34577539-C4DCE735-276B-4FDF-8B50-7A359D05D86FQ34742090-83EFE02B-47D5-4201-BA45-6FB01C94DD6CQ35019924-CC660EE7-4990-44D2-A58B-C539FFD3E909Q35023677-B5BB9E49-B2FD-466D-A9AA-82A6937F8CB0Q35185919-990639E1-4426-40E1-A53B-7479CBCE57D8Q35665921-DADBA148-0D07-4D0E-B86B-4C863F6D9315Q35857480-7FBCF204-06C5-43C7-9252-18F03496B94CQ35857567-84E57B01-4C19-4EAC-B721-9B029C2F34ADQ35947958-E992618E-4D57-46B6-8908-28ACABC66C46Q35970916-71246E69-D94A-4C0F-9E55-0588E9F86BC7Q36054188-EF985F33-2FF4-447C-8CFB-2CECF5E44685Q36239954-EB717036-FF2E-4FB5-90A3-06A9990D73FDQ36371387-2E7825F5-2805-4D5F-A296-B0CEFE9BFC6AQ36464609-0240ABB6-D3FE-4296-9EA6-7996CC1468E7Q36506821-7F0277D5-032D-435E-BA6D-003352EF7C6EQ36634790-C6D5DCB8-71C6-4EE2-BD81-E83F3A3A1D90Q36770954-47AC7148-300F-49CF-B868-214A51BDC83DQ37048079-3D9D5B0D-8CC5-4538-9259-34412762562BQ37052996-8419B230-311C-41E6-B13B-F2CFFF71F039Q37053027-9E95B83B-18EE-4F69-AEE4-89AA517FF6C6Q37083896-233993BF-624F-4057-84F1-C03A18F6A27AQ37130458-20934662-C4D5-4C3F-B2E1-5463E354F699Q37154153-B1FB12DD-3D5A-409B-B1FA-50472DDBBC8CQ37312729-1EA9F22E-2174-4E49-941F-6C1EEE345DB5Q38538043-54F9612E-7569-47E6-8518-8189185A5E2CQ39437445-EE3AF819-C9F6-4484-980B-46582207BF63Q39902009-31EC08F4-B36B-48DD-BFA6-FF5156797763Q42264071-5ECF9E7A-BFD7-40B1-9F3D-FDBB178F7A45Q43143940-11FEC2D8-FBEE-4583-8208-A0DC3DE0C919Q43825794-8D43BEA7-3E74-4082-AE8A-AC0D763AC826Q44430005-B427B736-2FE8-4BE5-98F4-AE0097DB85F1
P2860
Plasma viral load in HIV-1 and HIV-2 singly and dually infected individuals in Guinea-Bissau, West Africa: significantly lower plasma virus set point in HIV-2 infection than in HIV-1 infection.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh-hant
name
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@en
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@nl
type
label
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@en
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@nl
prefLabel
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@en
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@nl
P2093
P921
P1476
Plasma viral load in HIV-1 and ...... ction than in HIV-1 infection.
@en
P2093
Andersson S
Biberfeld G
Christopherson C
da Silva Z
P304
P356
10.1001/ARCHINTE.160.21.3286
P407
P577
2000-11-01T00:00:00Z